{"Clinical Trial ID": "NCT00082433", "Intervention": ["INTERVENTION 1:", "Ixabepilone + Capecitabine", "Ixabepilone in combination with capecitabine (control group): Ixabepilone 40 mg/m2 administered as an intravenous infusion (IV) of 3 hours at day 1 of each cycle only, plus oral capecitabine 1000 mg/m2 twice daily (2000 mg/m2 daily dose) x 14 days, followed by a week of rest.", "INTERVENTION 2:", "- Capecitabine", "Capecitabine alone: Capecitabine 1250 mg/m2 BID (2500 mg/m2 daily dose) x 14 days, followed by a week of rest."], "Eligibility": ["Patients should have received prior treatment including both anthracycline (doxorubicin or epirubicin) and taxane (paclitaxel or docetaxel).", "Patients who have not received treatment for metastatic disease must have relapsed within one year.", "Patients cannot have a history of brain metastases and/or leptomenates.", "Patients may not have grade 2 neuropathy or more severe neuropathy at the time of entry into the study.", "Patients may not have received epothilones and/or capecitabine (i.e., Xeloda) prior to treatment."], "Results": ["Performance measures:", "Overall survival (OS)", "For patients who had not died, survival was censored at the last date the patient was known to be alive. Median operating system with 95% CI estimated using the Kaplan-Meier product limit method.", "Duration: from date of randomization to death", "Results 1:", "Title of the arm/group: Ixabepilone + Capecitabine", "Ixabepilone in combination with capecitabine (summary group): Ixabepilone 40 mg/m2 administered as a 3-hour intravenous infusion (IV) only on day 1 of each cycle plus oral capecitabine 1000 mg/m2 twice daily (IND) (2000 mg/m2 daily dose) x 14 days, followed by a rest week.", "Total number of participants analysed: 609", "Median (95% confidence interval)", "Unit of measure: months 16.39 (14.95 to 17.91)", "Results 2:", "Title of the arm/group: Capecitabine", "Description of the arm/group: Capecitabine alone: Capecitabine 1250 mg/m2 BID (2500 mg/m2 daily dose) x 14 days, followed by a week of rest.", "Total number of participants analysed: 612", "Median (95% confidence interval)", "Unit of measure: months 15.64 (13.86 to 17.02)"], "Adverse Events": ["Undesirable Events 1:", "Total: 192/603 (31.84 per cent)", "ANEMIA 5/603 (0.83%)", "LEUKOPENIA 1/603 (0.17%)", "NEUTROPENIA 8/603 (1.33%)", "LYMPH PAIN NODE 0/603 (0.00 %)", "THROMBOCYTOPENIA 3/603 (0.50%)", "NEUTROPENIA FEBRILE 5/603 (0.83%)", "PERICARDITIS 1/603 (0.17%)", "NOT STABLE ANGINE 0/603 (0.00 %)", "- CARDIAC FAILURE 0/603 (0.00 %)", "SINUS TACHYCARDIA 0/603 (0.00 %)", "2/603 (0.33%)", "Adverse Events 2:", "Total: 205/595 (34.45 per cent)", "ANAEMIA 7/595 (1.18 %)", "LEUKOPENIA 8/595 (1.34%)", "NEUTROPENIA 18/595 (3.03%)", "LYMPH PAIN NODE 1/595 (0.17%)", "THROMBOCYTOPENIA 4/595 (0.67%)", "NEUTROPENIA FEBRILE 34/595 (5.71%)", "- PERICARDITIS 0/595 (0.00 %)", "NON-STABLE ANGINE 1/595 (0.17%)", "CARDIAC FAILURE 1/595 (0.17%)", "SINUS TACHYCARDIA 2/595 (0.34%)", "ATMOSPHERIC FIBRILLATION 0/595 (0.00 %)"]}